Glaxosmithkline Biologicals Sa

Glaxo Group Limited

Glaxosmithkline LLC

Id Biomedical Corporation of Quebec

Normand Blais

Jan Poolman

Steve Labbe

Marianne Dewerchin

Cindy Castado

Patrick Rheault

Denis Martin

Patrick Chomez

Dennis S Murphy

Jean-Louis Ruelle

James R Brown

Pascal Mettens

Philippe Marc Helene Dehottay

Philippe Goffin

Remi Palmantier

Guy Jean Marie Fernand Pierre Baudoux

Anne-Marie Gelinas

Anthony Pilorget

Clement Rioux

Alain Bergeron

Martine Marchand

Ventzislav Bojidarov Vassilev

Daniel Larocque

Martine Harvey

Jamila Louahed

Vincent Brichard

Remi M Palmantier

Martine Boyer

Virginie Van Scherpenzeel Thim

Yves Fradet

Corey Patrick Mallett

Anne-Marie Lanteigne

Sonya L Cyr

James Brown

Philippe Marc Dehottay

Guy Jean Baudoux

Corey Mallett

Jean-Pierre Baudoux

Jean-Loius Ruelle

Jean Louis Ruelle

Dennis Murphy

There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of:

Fusion proteins and combination vaccines comprisingProtein E and Pilin A

The present invention relates to compositions comprising() Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.

UspA2 protein constructs and uses thereof

The present invention relates to compositions comprisingProtein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.

Fusion proteins and combination vaccines comprising haemophilus influenzae Protein E and Pilin A

[object Object]

Compositions and methods related to periplasmic expression of a toxin including diphtheria toxin or CRM197 are provided herein.

Expression system

This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection.

Recombinant RSV vaccines

Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis.

Modified antigens

The present invention relates to the use of a immunogenic or immunostimulatory composition comprising aouter membrane protein (OMP) andLPS molecule in medicine and methods for preparing the composition.

Immunogenic composition

Antigen binding proteins, such as antibodies, which bind to human MAGE-A3, polynucleotides encoding such antigen binding proteins, and uses and manufacture thereof.

MAGE antigen binding proteins

Growing community of inventors

Laval, Canada

Normand Blais